Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $51.40

by · The Cerbat Gem

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has earned a consensus rating of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $51.40.

A number of equities analysts have weighed in on the stock. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th.

Read Our Latest Stock Report on DYN

Insider Activity

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at approximately $3,405,524.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $80,812.45. Following the sale, the insider now owns 140,375 shares of the company’s stock, valued at $4,849,956.25. The disclosure for this sale can be found here. Insiders sold 135,304 shares of company stock valued at $4,857,019 over the last three months. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DYN. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $573,000. Sei Investments Co. purchased a new stake in Dyne Therapeutics in the first quarter worth about $693,000. Rafferty Asset Management LLC increased its position in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after buying an additional 24,632 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Dyne Therapeutics in the first quarter worth about $810,000. Finally, Commodore Capital LP purchased a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $11,970,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Down 2.3 %

Shares of DYN stock opened at $33.83 on Friday. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -8.52 and a beta of 1.07. The business’s fifty day moving average is $40.26 and its 200 day moving average is $33.84. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Equities research analysts expect that Dyne Therapeutics will post -2.96 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

(Get Free Report

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Recommended Stories